To determine the effect of insulin on regional ce rebral blood flow (rCBF) and glucose metabolism (CMR g1 J, we performed quantitative dynamic PET scanning of labeled water (H 2 150) and deoxyglucose eSFDG) using two protocols in 10 diabetic men. In protocol A, to test reproducibility of the technique, insulin was infused at 1.5 mU·kg-1·min-1 twice (n = 5). In protocol B, low (0.3 mU·kg-1 ·min-1) and high (3 mU·kg-1·min-1) dose insulin was given on separate occa sions (n = 5). Euglycemia (5 mmollL) was maintained by glucose infusion. In protocol A, CMR g1 u was 6% higher during the first infusion, and catecholamines were also increased, in dicating stress. Blood flow was not different. Changing free insulin levels from 20.5 ± 4.8 to 19 1 ± 44.5 mUlL (P < 0.001, low versus high dose, protocol B) did not alter total or regional Abbreviations used: CMRg1u, cerebral metabolic rate for glucose; 18 FDG, radiolabeled fluorodeoxyglucose; IDDM, insulin-dependent diabetes mellitus; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; RSS, residual sum of squares; Val, volume of interest.
In many tissues of the body (and in particular in fat and muscle), insulin stimulates glucose uptake and phos phorylation. However the role of insulin in the metabolic processes of the brain remains unclear. Despite the pres ence of receptors for both insulin and insulin-like growth factor (IGF1) and their respective mRNAs (Kotzke et aI., 1995; Kenner et aI., 1995; Sable and Yeh, 1995) , many studies have suggested insulin does not affect rates of cerebral glucose utilization or cerebral function. This CMR g1 u (whole brain 36.6 ± 4.0 versus 32.8 ± 6.2 f,1moJ . 100 g-I'min-1 , P = 0.32) or CBF (41.7 ± 5.1 and 45.6 ± 9.7 mL·100 g-l . min-1 , P = 0.4) or rCBF. In cerebellum, CMR g1 U was lower than in cortex and the ratio between rate constants for glucose uptake and phosphorylation (KI and k3) was re versed. There are regional differences in cerebral metabolic capacity that may explain why cerebral cortex is more sensitive to hypoglycemia than cerebellum. Brain glucose metabolism is not sensitive to insulin concentration within the physiologic range. This suggests that intracerebral insulin receptors have a different role from those in the periphery. Key Words: Cere bral blood flow-Cerebral glucose metabolism-Diabetes mel litus-Insulin-Positron emission tomography.
view has been reinforced by recent data, using arterio venous difference techniques to measure cerebral glu cose uptake in vivo in man (Robinson et aI., 1994) . How ever, there are contrary data. Animal studies, often with insulin administered directly into the brain or ventricular system, have demonstrated effects of insulin on brain glucose metabolism (Grunstein et aI., 1985; Steffens et aI., 1988; Lucignani et aI., 1987) and feeding behavior (Schwartz et aI., 1992; Florant et aI., 1991) , and recent evidence from studies of hypoglycemia in human sub jects have suggested that insulin may influence brain function (Kern et aI., 1990 (Kern et aI., , 1994a (Kern et aI., , 1994b .Most of the work seeking an effect of insulin directly on cerebral glucose metabolism, especially that done in man, has measured total brain glucose metabolism. Yet there is evidence for regional differences in the brain's metabolic capacity (Lucignani et aI., 1987) . There are also regional differences in the accessibility of neuronal tissue to cir culating substances and in the density of insulin recep tors expressed (Grunstein et aI., 1985; Steffens et aI., 1988) . Thus it may be more relevant to examine the effects of insulin on cerebral metabolism regionally. The question of insulin's effects on cerebral glucose metabolism and the possibility of regional differences within the brain is important both clinically and in the understanding of clinical research. In patients with dia betes mellitus, peripheral insulin levels fluctuate widely in response to their therapy. An effect of insulin on ce rebral metabolism could then have clinical conse quences. A syndrome of altered responses to hypoglyce mia is recognized as a serious problem in the long-term management of insulin-dependent diabetes mellitus (IDDM) (Amiel et aI., 1987 , Rattarasarn et aI., 1994 . In this syndrome, the onset of symptomatic and protective responses to a falling blood glucose are delayed, occur ring at a lower plasma glucose level than impairment of at least some cognitive functions (Maran et aI., 1995) . Regional differences in the metabolic capacity of the brain may underlie this phenomenon, and potential re gional differences in insulin sensitivity of glucose me tabolism could contribute to the effects of diabetes and its therapy on brain function during episodes of acute hypoglycemia. Furthermore, if circulating insulin levels affect cerebral function during hypoglycemia, as sug gested by Kern and colleagues (1990 Kern and colleagues ( , 1994a Kern and colleagues ( , 1994b , then there is a theoretical risk that the production of high peripheral insulin levels in the management of diabetes may affect cerebral function acutely during euglycemia and potentially in the long term also. A recent study in dogs has demonstrated that raising insulin levels in the cerebral circulation during hypoglycemia dramatically enhances counterregulatory responses (Davis et aI., 1995) , confirming earlier work comparing different de grees of hyperinsulinemia during matched hypoglycemia from the same group (Davis et aI., 1992) with hypogly cemia in normal man, but these data are controversial (Kerr et aI., 1991; Diamond et aI., 1991; Mellman et aI., 1992; Lui et aI., 1991) . Despite this controversy, most studies of the cognitive and other neurogenic responses to hypoglycemia use hyperinsulinemic hypoglycemic challenges, making an understanding of the role of insu lin on regional cerebral glucose metabolism important in their interpretation. Positron emission tomography (PET) creates images of radioisotopes collected in tissues. After injection of radiolabeled fluorodeoxyglucose e S FDG, a glucose tracer that is taken up and phosphorylated by the same pathways as glucose but which then remains in the phos phorylated state within the cell), both the disappearance of the label from arterial blood and its accumulation in brain tissue are measured by PET. From these data, es timates of rates of glucose uptake and metabolism can be made in different brain regions in human subjects in vivo (Huang et al., 1980) . Using labeled water, PET scanning can also be used to provide quantitative information on regional cerebral blood flow (Raichle et aI., 1983) . For reasons that are not absolutely clear but which have been ascribed to subject unfamiliarity with the procedure, first scans tend to give slightly higher estimates of cerebral glucose metabolism than subsequent scans (Stapleton et aI., 1997) . The present study was therefore designed to investigate further the reproducibility of the techniques and the regional variations in cerebral blood flow and glucose metabolism in subjects with IDDM at euglyce mia and to examine the effects of hyperinsulinemia on these measurements.
MATERIALS AND METHODS
Ten male subjects were recruited, five for each of two stud ies. These numbers of subjects were estimated to give 80% power (90% confidence) of detecting a 20% change in either blood flow or glucose uptake regionally within the brain, based on published regional estimates (-10% variability) of these parameters (Bartlett et aI., 1988) . All subjects had insulin dependent (Type 1) diabetes mellitus and were C-peptide nega tive on fasting and postprandial measurements. Subjects for protocol A (reproducibility study) were a mean age of 40.0 ± 13.3 years (mean ± SD), with a mean body mass index of 24.35 ± 3.08 kg/m 2 , and had a disease duration of 21.0 ± 6.4 years. was begun 10 seconds before the injection of tracer and con tinued for 60 minutes. Arterial plasma glucose was maintained at 5 mmollL and continuous on-line monitoring of label in arterial blood was performed as during the H 2 ISO scan but with a lower flow rate (2 mL/min) after the first 15 minutes of scanning. Timed 2-mL hand-drawn arterial blood samples were taken at 5-minute intervals, I mL for cross-calibration of the fluid analyzer data with a well counter, which is daily cali brated to the PET scanner, and 1 mL for the plasma glucose measurements used to control the glucose infusion rate.
Samples for well counting were held on ice and subsequently centrifuged to separate the plasma fraction from whole blood, then accurately weighed for weight correction of counts. Ad ditional arterial blood samples for later measurement of free insulin were collected at clamp time 0, and 0, 30, and 60 minutes into the 1 8PDG scan, and for counterregulatory hor mones at study times 60, 90, 120, and 150 minutes.
At the end of the 1 8PDG scan, the insulin infusion was dis continued, the arterial line removed, and the patient given a subcutaneous dose of soluble insulin followed by a meal. The glucose infusion was discontinued once plasma glucose was consistently greater than 5.5 mmollL. Monitoring continued until this glucose level was maintained without glucose infu sion. The intravenous line was then withdrawn.
Before conducting second scans, the previous arterial can nulation site was inspected and the hand was reexamined for collateral circulation. Second scans were performed at the same time of day and under similar clamping conditions as the first. Protocol A: Reproducibility and regional variation of cerebral blood flow and glucose metabolism in insulin-dependent diabetic men
The study protocol was as described above. Each subject was studied with PET twice, 3 to 4 weeks apart. On each occasion, the insulin infusion dose was the same, 1.5 mU·kg-1. min-1 .
Protocol B: Effect of insulin on regional cerebral blood flow and glucose metabolism in insulin dependent diabetic men
The admission and overnight glycemic control periods were conducted exactly as in protocol A. Cannulation and scanning procedures were also identical. The only significant difference from protocol A was in the insulin infusion doses used during the two PET scans. In protocol B, different doses were used for the two scans. In random order, either 0.3 mU·kg-l·min-1 (low dose) followed at the second visit by 3.0 mU·kg-1 ·min-1 (high dose) or 3.0 mU·kg-1 ·min-1 (high dose) followed by 0.3 mU·kg-1 ·min-1 (low dose) was used, with the subject unaware of the infusion dosage,
Measurements and calculations
After collection and archiving of the data, the dynamic PET scans were registered into the same volumetric orientation as the MRI scan using a multiresolution voxel similarity approach with automated iterative processing, followed by visual cor roboration of the resulting registration (Studholme et aI., 1997).
This process was performed initially on a time-summed static PET image, and the transformation then applied to each dy namic frame; in the case of movement during the scan (moni tored and noted with reference to the laser grid), individual frames could be registered (although this was in fact only nec essary for one frame in the entire study). An anatomic template of predefined regions of interest (ROI) was adapted to the individual anatomy of each subject on his MRI scan. The focus of the ROI in this study was the cortical gray matter over many different anatomic areas. Regions were placed and labeled in 28 separate cortical gyri on individual MRI planes, and regions appearing on more than one MRI plane were summed across those planes to create volumetric ROI (VOl) for that gyrus or structure. In addition to the cortical VOl, regions were defined in cerebellar gray matter, thalami, hippocampi, caudate, brain stem, and the area of the hypothalamus. The PET data coreg istered in the VOl were analyzed.
The arterial tracer curve was calibrated against the timed well-counter data to bring the measurement into the same units and timescale as the scan data. During this preprocessing of the tracer activity curve, artifacts from sampling and flushing the line were removed by a simple editing process.
The water study of cerebral blood flow was analyzed using a nonlinear least squares fitting procedure applied to the arterial input function and the regional tracer time-activity curves, us ing the VOl and registration protocols as above. The technique for derivation of regional cerebral blood flow from H 2 1 50 scans involves modification of the autoradiographic technique developed by Kety as described by Raichle et al. (1983) , (Kety and Schmidt, 1948) , whereby the tissue and arterial activities of a freely diffusible inert tracer are measured for a known time. Data from the 1 8FDG study were analyzed to obtain the rate constants for glucose uptake (Kl), glucose egress (k2), glucose phosphorylation (k3), and dephosphorylation (k4) as specified in the three-compartment model described by Sokoloff et al. (1977) , modified by Phelps for use with FDG (Phelps et aI., 1979) , and using a lumped constant to relate the tracer to tracee behavior between 18FDG and natural glucose (Reivich et aI., 1985) . A nonlinear least squares fitting procedure (Neider and Mead, 1965 ) was applied to the arterial input function (the arterial tracer curve) and the regional brain tracer time-activity curves. A term accounting for the tissue blood volume was also estimated in the model. The "global" metabolic rate for glu cose in each ROI was calculated according to the following equation:
where PG is plasma glucose, and LC is a lumped constant of 0.52 (Reivich et aI., 1985) .
Of approximately 450 single defined regions per study, a small number (-2%) could not be fitted using the described paradigm and standard estimates. Rather than attempting indi vidual fitting with different initial estimates (and thus possibly introducing bias), these data were omitted from further analy sis.
Plasma glucose was measured using a glucose oxidase method. Catecholamines were measured by high-pressure liq uid chromatography with electrochemical detection (Macdon ald and Lake, 1985) and cortisol (Cunnah et aI., 1987) , gluca gon, growth hormone (Mazlan, 1989) , and free insulin concen trations by radioimmunoassay (Hanning et aI., 1985) . Paired studies were measured in the same assay runs. The intra-assay variation for any assay was less than 10%.
Statistical analyses
Data are presented as mean ± SD. Each subject was paired with his own second study and the regional analyses subjected to normality testing and parametric processing (paired I testing;
minitab, Minitab Inc., State College, PA, U.S.A.). Because ROI (as presented in the figures) are not truly independent variables within one brain area (e.g., cortex), the statistical analyses are performed on the grouped data for each of six larger regions as in Table 2 . For multiple comparisons (e.g., cerebral blood flow across several brain regions), differences were first sought by one-way analysis of variance, before t tests were applied to pairwise comparisons. Fit accuracy (residual sum of squares, RSS) and variance of the data were checked before making comparisons between the parameters derived from the fitting processes. These data, along with covariance of k values one to another, are discussed in the appendix.
RESULTS
Protocol A: Reproducibility and regional variations in cerebral blood flow and glucose metabolism in diabetic man
During euglycemic clamping, free plasma insulin was 96.1 ± 31.4 mU/rnL at steady state in first scans and 99.3 ± 45.3 mU/mL in second scans, P = 0.44. Arterial plasma glucose was maintained throughout at 4.98 ± 0.04 and 4.99 ± 0.03 mmol/L, in first and second scans, respectively, P = 0.2. Glucose infusion rates during the 90 minutes of H 2 15 0 and 18 FDG PET scanning were 4.75 ± 0.87 mg/kg per minute and 4.84 ± 1.62 mg/kg per minute, respectively, P = 0.88. In first scans, catechol amine levels were high at baseline and remained elevated throughout ( Table 1 ). In second scans, levels rose slightly as scanning proceeded but did not achieve the levels of first scans (Table 1) . Glucagon, cortisol, and growth hormone levels did not rise significantly during scanning, but were consistently higher in scan I than scan 2 (see Table 1 ).
Total cerebral blood flow was not significantly differ ent between first and second scans (47.4 ± 5.4 mL·100 g-1 'min-1 first scans versus 47.1 ± 6.8 rnL·100 g-l 'min-I in second scans, P = 0.94). The intraindividual variation of blood flow is best described by the mean of differ ences between the two scans rather than the difference of means, which describes the interindividual variation. The former is shown in Table 2 , and confirms that the intra individual variation of this technique is also low. Brain blood flow in individual regions of interest at the two insulin levels are shown in Fig. 1 , lower panel. When blood flow was calculated for major brain regions by summation of the relevant ROI data, there were no sig nificant differences between first and second scans but flow was significantly slower in the brainstem than in the cortex or cerebellum on both occasions (first scans, brain stem 41.7 ± 4.6 versus cortex 47.5 ± 7.3 mL·100 g-1 . min-1
, P = 0.06 and cerebellum 50.2 ± 4.9 mL·100 g-I ·min-I , P = 0.001; second scans, brainstem 39.9 ± 7.8 versus cortex 48.1 ± 9.3 mL·100 g-I 'min-I , P = 0.03 and versus cerebellum 46.9 ± 10.9 mL·100 g-I 'min-I ,
Cerebral metabolic rate for glucose (CMR g1 u) across the whole brain was slightly higher in first scans (41.9 ± 7.4 versus 39.4 ± 3.2 ILmol·100 g-l ·min-1 ) than in sec ond scans, for summed whole brain regions (P = 0.59),
representing approximately a 6% change. This was con sistent across all regions of interest ( Fig. 1, upper panel) , b ut did not achieve significance even when summed re gions of interest were calculated (see below). In both sets of scans, however, CMR g1 u was consistently lower in cerebellar regions than in cerebral cortex: summed CMR g1 u for frontal cortex 45.0 ± 8 ILmol·100 g-I 'min-I first scans and 42.8 ± 4.4 ILmol·100 g-I ·min-I second scans (P = 0.44) versus CMR g1 u across the cerebellum 36.6 ± 7.6 and 33.4 ± 3.0 ILmol·100 g-I 'min-1 (P = 0.20). The difference between the values in the cortex and cerebellum was significant in each study, P = 0.05 for first scans and 0.01 for second scans. The intraindi vidual variation of the CMR g1 u calculation is shown in Table 2 . As shown in Table 3 , rate constants were also different between cortex and cerebellum. K1 was lower in the cerebral cortex by a factor of 0.658 whereas k3 was higher by a factor of 1.367. The ratio between Kl and k3 was therefore reversed in the cerebellum (Fig. 2) . This finding was consistent in the second scans. : t �:
: t 1 f1t t �� � �r. ���ij ���� Free plasma insulin was elevated from 16.7 ± 5.82 mUlL at baseline to 20.5 ± 7.7 mUlmL during the 0.3 mU·kg-1 ·min-1 infusion and from 26.0 ± 18.6 at baseline to 191.0 ± 38.3 mUlmL during the 3.0 mU·kg-l ·min-1 infusion, P < 0.0001. Arterial plasma glucose levels were maintained at 5.05 ± 0.04 and 5.11 ± 0.05 mmol/L throughout each study, P = 0.2. Glucose infusion rates required to maintain euglycemia during the 90 minutes of the 18 FDG scans were 1.65 ± 0.88 mg/kg per minute during low-dose and 7.09 ± 1.17 mg/kg per minute dur ing high-dose insulin infusion, P < 0.0001. Catechol amine, glucagon, and growth hormone levels did not rise significantly in either study, although cortisol levels fell slowly over time, in normal diurnal rhythm. Total brain blood flow was not significantly different between the two levels of insulin, 4l.7 ± 5.3 mL·100 g-I 'min-I low-dose versus 45.6 ± 6.3 mL·100 g-l 'min-I high-dose insulin infusion, P = 004. Brain blood flow in individual regions of interest at the two insulin levels are shown in Fig. 3 , bottom panel, and although there were differences between regions, insulin had no significant effect on any brain blood flow measure. When blood flow was calculated for major brain regions by summa tion of the relevant ROI data, there were no significant differences between the two studies: cortex, 4l .1 ± 5.5 mL· I00 g-I 'min-1 (low dose) versus 45.1 ± 9.0 mL·100 g-I 'min-I (high dose), P = 0.36; cerebellum, 43.9 ± 2.8 mL·100 g-I 'min-1 (low dose) versus 48.8 ± 10.2 mL·100 g-I 'min-1 (high dose), P = 0045.
Cerebral metabolic rate for glucose across the whole brain was not different between the two studies (36.6 ± 4.4 versus 32.8 ± 5.6 f.Lmol·100 g-1 . min-1 , low-versus high-dose infusion, P = 0.32). To be certain that the "practice effect" of lower CMR g lu in second scans was not concealing a minor insulin effect, we also performed the analysis after increasing values for all data from sec ond studies by 6%. This gave us estimates of 38.3 ± 5.3 f.Lmol·100 g-I 'min-1 and 33.7 ± 4.6 f.Lmol·100 g-l . min-1 for the low-and high-dose insulin studies, respectively, P = 0.2. CMR g lu for individual regions of interest are shown in Fig. 3 , upper panel. Although there is variation between regions, there were no significant differences between CMR g lu at the two insulin levels in any given region. When CMR g lu of major brain regions was deter mined by summation of ROJ within them, insulin had no appreciable effect: CMR g lu for the cortical gyri was 40.8 ± 504 f.LmoJ . 100 g-l . min-1 low-dose versus 36.5 ± 6.7 f.Lmol·100 g-I 'min-1 high-dose insulin infusion, P = 0.3, whereas CMR g lu across the cerebellum was lower at 31.7 ± 6.6 /-Lmol·100 g-I 'min-1 low-dose and 29.1 ± 4.3 /-Lmol·100 g-1 'min-1 high-dose insulin, P = 0.6. At both low-and high-dose insulin, the cortical CMR g \u was sig nificantly higher than the cerebellar values, P = 0.040 for low-dose and 0.011 for high-dose insulin infusion. The individual rate constants for cerebral glucose up take and metabolism were similarly unaffected by hy perinsulinemia, but the same relationships between rate constants in the different brain regions were noted (see Table 3 ).
DISCUSSION
Debate about the role of insulin in cerebral glucose metabolism has not been resolved. Although early data suggest that insulin does not affect glucose metabolism in brain tissues (e.g., Goodner and Berrie, 1977; Hom et aI., 1984; Brooks et aI., 1986) , the demonstration of in sulin receptors and insulin receptor mRNA in neuronal tissue raises the question of their functional significance (Kotzke et aI., 1995; Kenner et aI., 1995; Sable and Yeh, 1995) . In vitro data suggest that insulin may alter neu ronal metabolism, there is evidence that insulin can pen-J Cereh Blood Flow Metab. Vol. 18. No.2. 1998 etrate the blood brain barrier and enter the brain (Steffens et aI., 1988) , and recent animal studies using autoradi ography demonstrated regional variations in insulin up take and insulin-enhanced glucose metabolism (Lucig nani et aI., 1987) . Quantitative study, however, o f rate constants for glucose transport in rats suggests that the overall effect of this in terms of brain spatial distribution of glucose is small (-10%) compared with insulin-sensitive tissues, even at a high insulin dose. Recent human studies examining whole brain uptake by an arteriovenous difference technique failed to find any evidence for an effect of insulin in humans in vivo (Robinson et aI., 1994) , but studies of evoked potentials during hypoglycemia induced by dif ferent types of insulins found differences in the magni tude of hypoglycemia-associated abnormalities (Kern et aI., 1990 (Kern et aI., , 1994a (Kern et aI., , 1994b . The authors suggested that these differences may relate to different intracerebral in sulin concentrations subsequent to different physical properties of the insulins, implying that insulin does af fect at least some cerebral functions in man. This has clinical implications in view of suggestions that different insulin preparations may affect hypoglycemic responses differently (reviewed in Amiel, 1995) . Furthermore, al though the evidence for an effect of insulin on counter regulatory responses to hypoglycemia in man is contro versial (Kerr et aI., 1991; Diamond et aI., 1991; Lui et aI., 1991; Davis et aI., 1993; Mellman et aI., 1992) , a recent study using selective catheterization to elevate cerebral blood insulin levels during hypoglycemia in dogs sug gests that insulin may affect brain behavior in hypogly cemia (Davis et aI., 1995) . The question is of more than academic interest, because of the possibility that hyper insulinemia may affect brain function in diabetic patients both acutely, as in response to hypoglycemia, or chroni cally. To date, most studies of the effects of insulin on brain glucose metabolism either have been in animals or have examined whole brain (Hertz et aI., 1981; Grill et aI., 1990) . Studies in non-insulin-dependent diabetic subjects have been done and showed little effect of in sulin, but these subjects were probably obese and likely to have been systemically insulin resistant (Eastman et aI., 1990) . Blood flow was not examined. We therefore set out to look for effects of insulin on regional brain glucose metabolism, using 18 FDG PET and euglycemic insulin clamp techniques to control blood glucose and insulin levels in normal-weight male subjects with stable IDDM. Because brain function is effectively glucose de pendent and the brain stores negligible quantities of glu cose, blood flow supplying the brain's glucose needs is critical to normal brain function; we examined this also in our studies. Our data support the hypothesis that, de spite an abundance of insulin receptors, insulin in physi ologic or therapeutic quantities has no appreciable effect on 18 FDG metabolism in any brain region.
Our initial study was performed to test the reproduc ibility of the techniques. Our data confirmed previous studies, with a low intraindividual variation in estimates of CMR g 1u and blood flow. The magnitude of interindi vidual variation in blood flow was slightly lower than recent similar studies, perhaps reflecting the close sub ject matching (Ohta et aI., 1996) , but of the same order of magnitude. Retrospectively, using these data to recalcu late our power, we find that the original figures for CMR g 1u and blood flow are broadly confirmed; region ally we would expect to detect between 12% and 25% changes in either of these parameters. Individual rate constants show varying degrees of codependence (see Appendix), making variability somewhat higher than global terms such as CMR g 1u' As a result, the differences we would expect to detect in these (90%) are respec tively higher; 30% to 40% in Kl and k3, and up to 80% in k2. These figures are large but smaller than would occur with this study design in insulin-sensitive tissues such as muscle. They explain why the small trends seen in our data (e.g., the order effect) do not reach signifi cance; however, clinically significant changes in insulin sensitivity should not have been missed.
The finding of an order effect related to anxiety in repeated studies has been described previously (Staple ton et aI., 1997) . However, Bartlett et aI. (1988) associ ated lower CMR g 1u with stress, assessed by questionnaire and physiologic responses such as pulse rate. In our study, first estimates of CMR g 1u were approximately 6% higher than second runs, but with no change in regional blood flow, and this was associated with relatively high catecholamine levels on the first occasion. To our knowl edge, this has not previously been examined. Our data would therefore support the suggestion that stress is as sociated with increased CMR g 1u' One possible explana tion for these apparent discrepancies may lie in the fact that the earlier study was also seeking a diurnal variation in CMR g 1u and performed repeat scans at different times of day. Morning CMR g 1u was lower than that of the afternoon. Our studies were all done at approximately the same time of day and elimination of such confounding variables may have given the different result. In any event, all the effects (order and time of day) are relatively small. Because of the radiation doses involved, it is not practical to eliminate the order effect by repeated studies. Randomization of studies is therefore particularly impor tant and power calculations taking into account a poten tial variation in results are essential in study design. In our second study, examining the effects of different lev els of hyperinsulinemia, reducing the calculated CMR g1 u of all second studies by 6% did not influence outcome.
Positron emisson tomography allows the study of blood flow and glucose metabolic rate in specific brain regions. It does however have limitations and one of these is the resolution of the technique as currently avail-able. Recent work has located the most dense concentra tion of insulin receptors in the hypothalamus, hippocam pus, olfactory lobes, and cerebellum. The hypothalamus is also of particular interest in view of recent data sup porting its role as the putative glucose sensor-that part of the brain that recognizes a falling glucose supply (Borg et aI., 1995) , probably as a falling rate of intracel lular metabolism (Borg et aI., 1997) , and triggers the counterregulatory responses. We have found no evidence to support the suggestion that glucose metabolism in the area of the hypothalamus is affected by insulin. The reso lution of the PET scan is not really adequate to examine so small an area as an hypothalamic nucleus, and PET data from the region of the hypothalamus is particularly prone to partial volume effects. Hoffman et aI. (1979) states that partial volume effects will be significant for objects of less than twice the full width at half maximum of the scanner. However, although some studies have suggested an effect of insulin is localized to this particu lar area of the brain (Lucignani et aI., 1987) , others have evidence of a more widespread phenomenon (Grunstein et aI., 1985) , including the cerebral motor cortex, albeit reporting unexpectedly a fall in the rate of regional ce rebral glucose metabolism. Furthermore, the data from Germany (Kern et aI., 1990 (Kern et aI., , 1994a ) suggest a more extensive insulin effect on cerebral function (and by implication metabolism), including the cerebral cor tex and brain stem. These can be easily isolated and visualized with PET, and we can be confident that insulin does not affect metabolic action in these areas of human brain. In this conclusion we would concur with Eastman et aI. (1990) , although for a different insulin range and in a different set of subjects. However, unlike them we do not see any significant change in k4 as a result of insulin infusion. Indeed, considering the changes to the arterial time-activity curves of the 18 FDG tracer (as a result of increased peripheral glucose uptake in the presence of higher insulin doses), the net result in terms of cerebral glucose metabolism is negligible. This is the first demonstration in man that the cerebel lum has different glucose kinetics from more rostral ar eas of brain, although it is consistent with earlier pub lished data from animals (Sokoloff et aI., 1977) . Studies in rats have described a higher rate of tissue glucose extraction from blood in the cerebellum and shown that the cerebellum has a higher rate of glucose influx to glucose utilization (La Manna and Harik, 1985) . This is compatible with the. relatively high Kl in our human data. Our data suggest that, although at euglycemia glu cose uptake rather than phosphorylation is the rate limiting step in rostral brain regions (the rate of the former being about 50% the rate of the latter, Cremer et aI., 1981) , this may not be the case in the cerebellum. Furthermore, if the cerebellum is more efficient in ex tracting glucose from the circulation, one might expect cerebellar functions to be more resistant to hypoglyce mia, when glucose transport becomes the rate-limiting step. This is supported both by animal studies and the available human data. The mechanism of increased cer ebellar efficiency for glucose uptake is not known. It is possible that the cerebellum or the endothelium of the cerebellar circulation expresses more glucose transport ers than the cerebral cortex. It is also possible that the microcirculation of the cerebellum is different. There is evidence that the volume of distribution of L-glucose is greater in cerebellum (Betz and Ianotti, 1983) . The com bination of improved glucose extraction and decreased CMR g Ju in cerebellar regions will be expected to leave higher glucose and glycogen content in the cerebellar tissue and this has been demonstrated in animals (Ratcheson et aI., 1981) . Together these processes are likely to result in tissue that is relatively resistant to hypoglycemia. This has also been demonstrated in ani mal studies (e.g., Brierley et aI., 1971; LaManna and Harik, 1985) and to some extent in man.
In conclusion, our data find no detectable effects of physiologic levels of circulating insulin on glucose up take in man in any brain region studied. This is consistent with earlier studies of whole brain, and shows that hy perinsulinemic clamping can be used in conjunction with positron emission tomography to study regional brain metabolism in man. We find a first-order effect of re peated studies, whereby CMR g Ju increases with raised catecholamine levels, but the effect is small. There are regional differences in brain glucose metabolic capacity that may explain regional differences in the sensitivity of brain tissue to hypoglycemia. These differences may in future be exploited to devise ways of protecting brain metabolism and function during hypoglycemia as expe rienced by insulin and sulfonylurea treatment of diabetes mellitus. 
